Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

The New England Journal of Medicine (NEJM) published results from part 1 of the ongoing phase 3 ESSENCE trial which ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

So, there's this scientist, Arun Sanyal, M.D., who's the director of the VCU Stravitz-Sanyal Institute for Liver Disease and ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with ...

In a new study, Ozempic - a drug sold to help with obesity and diabetes - is attributed to helping this disease.

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.